| Literature DB >> 12060125 |
Naohi Sahara1, Akihiro Takeshita, Kazuyuki Shigeno, Shinya Fujisawa, Kaori Takeshita, Kensuke Naito, Michio Ihara, Takaaki Ono, Sadahiro Tamashima, Kenji Nara, Kazunori Ohnishi, Ryuzo Ohno.
Abstract
We analysed CD56 expression in 70 patients with multiple myeloma (MM) to determine its clinicopathological and prognostic significance. Fifty-five (79%) patients were CD56+. CD56- patients (n = 15) had higher beta2 microglobulin levels and a higher incidence of extramedullary disease, Bence Jones protein, renal insufficiency and thrombocytopenia than CD56+ patients. Their myelomas more frequently had a plasmablastic morphology. Overall survival was significantly lower in CD56- than CD56+ patients (22 vs 63 months, P = 0.0002). We conclude that CD56- MM is a discrete entity associated with more aggressive disease. The higher incidence of plasmablastic cases suggested that CD56- MM may develop from a less mature plasma cell than CD56+ MM.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12060125 DOI： 10.1046/j.1365-2141.2002.03513.x
Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998